Pharma firm striving for a world with no infectious disease

Plan to use extensive network to become a ‘one-stop shop’ for big pharma

Jeremy Skillington, CEO at Poolbeg Pharma. Picture: Jason Clarke

It has been a steady few weeks for Poolbeg Pharma, after a successful trading launch on the Alternative Investment Market, London Stock Exchange’s space for small- and medium-size growth companies.

Having been spun out from Open Orphan, the new company raised £25m (€29m) in its initial public offer, increased through investor demand from an original target of £20m (€23.4m).